monoclon antibodi etoposide/cytosin arabinosid combin ex vivo purif bone marrow acut nonlymphocyt leukemia pharmacolog immunolog method ex-vivo bone marrow BM acut nonlymphocyt leukemia anll effect etoposid micrograms/ml cytosin arabinosid ara mg/ml tandem monoclon antibodi moab chosen stem cell pool major patient anll agent incub drug complement-medi lysi ara log human anll cell line drug concentr log normal commit granulocyte/macrophag stem cell cfu-gm singl exposur complement drug-treat cell log similar pharmacolog agent differenti kill clonagen leukem cell colony-form unit-leukemia cfu-l patient anll drug blast normal cfu-granulocyte-macrophag cfu-gm log cfu-l kill drug concentr log cfu-gm log anll cfu-l sequenti treatment synergi log cfu-l normal cfu-gm pool two-stag long-term BM cultur pluripot stem cell elimin drug/moab combin differ cfu-gm bfu-e product week cultur treat cell untreat control spare earli progenitor cell sequenti ex treatment human anll cfu-l complement-medi lysi cfu-l earli normal hematopoiet progenitor cell effect way BM 